E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder*1

Ross, Jeffrey S.; Rosario, A. D. Del; Figge, Helen L.; Sheehan, Christine E.; Fisher, Hugh A.G.; Bui, Hai X.

doi:10.1016/0046-8177(95)90081-0

Cited by 51 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Membranous staining for E–cadherin was absent in the mesenchymal element compared to the epithelial cancer cells in the same tumor. Our results support the relevance of E–cadherin in tumor progression that has been reported previously [31, 32, 33]. It is also supported by the notion that transdifferentiation recapitulates an embryogenic program in which epithelial to mesenchymal transitions occurs during morphogenetic rearrangement in association with downregulation of cadherins [23].…”

Section: Discussionsupporting

confidence: 92%

“…Previous studies have demonstrated that loss of E–cadherin expression was associated with loss of differentiation in a variety of cancers, including bladder cancer [31, 32, 33]. Since acquisition of mesenchymal characteristics typically takes place late in tumor progression, we examined the expression pattern of E–cadherin in relation to differentiation status.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin

et al. 2000

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin

et al. 2000

View full text Add to dashboard Cite

“…In breast (Gamallo et al, 1993;Moll et al, 1993;Lipponen et al, 1994), gastric (Oka et al, 1992;Shino et al, 1995), colorectal (Dorudi et al, 1993;Kinsella et al, 1993) and prostatic (Umbas et al, 1994) carcinomas, reduced E-CD immunoreactivity has been shown to be associated with progressive state and increased grade. In transitional-cell carcinoma of the urinary bladder (Bringuier et al, 1993;Otto et al, 1994;Ross et al, 1995;Syrigos et al, 1995;Lipponen and Eskelinen, 1995), a relationship has been observed between reduction of E-CD immunoreactivity and grade, tumor size and metastasis. However, few studies have investigated the prognostic importance of E-CD immunoreactivity in upper-urinarytract cancer.…”

mentioning

confidence: 99%

E-cadherin expression in upper-urinary-tract carcinoma

et al. 1997

View full text Add to dashboard Cite

Carcinoma of the upper urinary tract is a relatively rare neoplasm, and few studies have dealt with clinicopathological findings and prognosis in a large number of cases. The purpose of our investigation was to look for a possible relation between E-cadherin (E-CD) immunoreactivity and clinico-pathologic findings or clinical outcome in transitional-cell carcinoma of the upper urinary tract (TCC-UUT). To this end, we investigated E-CD immunoreactivity in 154 cases of TCC-UUT. E-CD immunoreactivity was recognized as being of ''normal'' pattern in 29.2% of samples. The relationship between E-CD immunoreactivity and clinicopathologic findings was significant for stage, grade and pattern of growth. The 5-year disease-free rate for 147 cases and 5-year overall survival rate for 154 cases were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth and E-CD immunoreactivity all had a significant effect on disease-free and overall survival rates. In the final models of multivariate analysis, however, we found that, for disease-free survival and for overall survival, only stage was a factor for progression or prognosis. Detection of E-CD immunoreactivity appears to be of limited value in deciding the prognosis of TCC-UUT. Int.

show abstract

“…For instance, loss of E-cadherin in cancer cell lines has been associated with loss of epithelial morphology and acquisition of tumor cell motility and invasion (32). In urinary bladder cancer, loss of E-cadherin has been associated with high-grade urothelial carcinomas, development of metastasis, and poor cancer prognosis (33,34).…”

mentioning

confidence: 99%

Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder

Abraham¹,

Knapp

Liu

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis.The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers. The purpose of this work was to determine the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and determine EphA2 as a new target for therapy in bladder cancer. Experimental Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, respectively, in bladder cancer cell lines. In addition, the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was determined by immunohistochemistry. Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system.

show abstract

E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder*1

Cited by 51 publications

References 21 publications

Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin

Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin

E-cadherin expression in upper-urinary-tract carcinoma

Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder

Contact Info

Product

Resources

About